AstraZeneca breast cancer drug granted priority review by US FDA
25th Jul 2022 07:12
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Enhertu metastatic breast cancer asset had been granted priority review status in the US following results from its DESTINY-Breast04 trial.
Read moreAstraZeneca breast cancer drug granted priority review by US FDA
25th Jul 2022 07:12
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Enhertu metastatic breast cancer asset had been granted priority review status in the US following results from its DESTINY-Breast04 trial.
Read moreAstraZeneca's HER2-positive breast cancer drug receives EU approval
19th Jul 2022 07:02
(Sharecast News) - Drugmaker AstraZeneca's Enhertu has received European Union approval to be used as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
Read moreAstraZeneca agrees to acquire TeneoTwo
5th Jul 2022 07:04
(Sharecast News) - Drugmaker AstraZeneca has agreed to acquire TeneoTwo and its clinical-stage T-cell engager in a deal worth up to $1.26bn as part of an effort to accelerate the development of the potential new medicine for B-cell haematologic malignancies.
Read moreCovid-19 cases surge during latest week due to BA.4 and BA.5 Covid-19 sub-variants
1st Jul 2022 13:22
(Sharecast News) - The number of new coronavirus cases in Britain jumped again during the preceding week, likely due to the more infectious BA.4 and BA.5 variants of the Omicron variant of Covid-19.
Read moreOxford Biomedica signs new Covid vaccine deal with AstraZeneca
1st Jul 2022 07:03
(Sharecast News) - Oxford Biomedica has signed a new three-year deal to make AstraZeneca's Covid-19 vaccine beyond this year when the original agreement expires, the company said on Friday.
Read moreAstraZeneca receives positive interim results from lung cancer drug trial
30th Jun 2022 07:13
(Sharecast News) - Pharmaceutical giant AstraZeneca has received positive results from a planned interim analysis of the AEGEAN Phase III trial on its resectable non-small cell lung cancer drug.
Read moreAstraZeneca's breast cancer drug recommended for EU marketing authorisation
27th Jun 2022 07:04
(Sharecast News) - Drugmaker AstraZeneca said on Monday that Lynparza, its HER2-negative high-risk early breast cancer drug, has been recommended for marketing authorisation in the European Union after demonstrating "a statistically significant and clinically meaningful" improvement in invasive disease-free survival.
Read moreCiti reiterates 'buy' on AstraZeneca on the back of trial results for Enhertu against breast cancer
22nd Jun 2022 10:06
(Sharecast News) - Analysts at Citi reiterated their 'buy' recommendation for shares of AstraZeneca following the release of the results of the DESTINY-Breast 04 clinical trial using its Enhertu treatment against metastatic breast cancer.
Read moreAstraZeneca receives 'positive' results from Phase III trial on eplontersen
21st Jun 2022 08:13
(Sharecast News) - Drugmaker AstraZeneca has received positive high-level results from an interim analysis of its NEURO-TTRansform Phase III trial on eplontersen, the group's hereditary transthyretin-mediated amyloid polyneuropathy drug candidate.
Read moreBerenberg stays at 'buy' for AstraZeneca after trial results for Enhertu against breast cancer
6th Jun 2022 17:48
(Sharecast News) - Analysts at Berenberg reiterated their 'buy' recommendation with a 120.0p target price for shares of AstraZeneca following the release of the company's clinical trial results for its treatment against metastatic breast cancer.
Read moreAstraZeneca-Daiichi's Enhertu reports positive survival rate results
6th Jun 2022 07:47
(Sharecast News) - A treatment for breast cancer developed by AstraZeneca and Daiichi Sankyo has been shown to double the progression-free survival rates of patients compared with chemotherapy, according to trial data released on the weekend at a conference.
Read moreAstraZeneca autoimmune treatment meets trial endpoint
5th May 2022 08:42
(Sharecast News) - AstraZeneca said its treatment for an autoimmune disease that attacks the central nervous system had met a primary endpoint in a phase 3 trial.
Read moreAstraZeneca's Imfinzi granted priority review in the US
4th May 2022 07:42
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that a supplemental biologics license application for its Imfinzi asset, in combination with standard-of-care chemotherapy, had been accepted and granted priority review in the US for patients with locally advanced or metastatic biliary tract cancer.
Read moreAstraZeneca reiterates guidance after first quarter growth
29th Apr 2022 08:23
(Sharecast News) - AstraZeneca said on Friday that its total revenue for the first quarter surged 60% to $11.39bn (£9.07bn), with growth across the company seeing it reiterate its full-year guidance.
Read more